Interactions between Troleandomycin and Vorapaxar

Troleandomycin has a major potential interaction with Biliary Obstruction.

Troleandomycin is primarily excreted by the liver and may accumulate in patients with impaired hepatic function. In addition, the use of troleandomycin has been associated with an allergic type of cholestatic hepatitis, particularly in patients receiving the drug for more than 2 weeks or given repeated courses. Therapy with troleandomycin should be administered cautiously in patients with liver and/or biliary disease. Liver function tests should be monitored during prolonged or repeated courses of therapy, and the drug discontinued if abnormalities develop.

Vorapaxar has a major potential interaction with Bleeding Associated with Coagulation Defect.

Vorapaxar increases the risk of bleeding and it is contraindicated in patients with active pathological bleeding such as intracranial hemorrhage or peptic ulcer. In other patients, consider the underlying risk of bleeding before initiating therapy. General risk factors include older age, low body weight, reduced renal or hepatic function, history of bleeding disorders, and use of certain concomitant medications. The use of warfarin and other anticoagulants should be avoided. Bleeding should be suspected in any patient who is hypotensive and has recently undergone coronary angiography, percutaneous coronary intervention (PCI), coronary artery bypass graft surgery (CABG), or any other surgical procedure.

Vorapaxar has a major potential interaction with Cerebral Thrombosis/Embolism.

Vorapaxar is contraindicated in patients with a history of stroke, transient ischemic attack (TIA), or intracranial bleeding. The risk of intracranial bleeding is higher in these patients.

Vorapaxar has a major potential interaction with Hemorrhagic Stroke.

Vorapaxar is contraindicated in patients with a history of stroke, transient ischemic attack (TIA), or intracranial bleeding. The risk of intracranial bleeding is higher in these patients.

Vorapaxar has a major potential interaction with Hemorrhagic Stroke.

Vorapaxar increases the risk of bleeding and it is contraindicated in patients with active pathological bleeding such as intracranial hemorrhage or peptic ulcer. In other patients, consider the underlying risk of bleeding before initiating therapy. General risk factors include older age, low body weight, reduced renal or hepatic function, history of bleeding disorders, and use of certain concomitant medications. The use of warfarin and other anticoagulants should be avoided. Bleeding should be suspected in any patient who is hypotensive and has recently undergone coronary angiography, percutaneous coronary intervention (PCI), coronary artery bypass graft surgery (CABG), or any other surgical procedure.

Vorapaxar has a major potential interaction with History - Cerebrovascular Disease.

Vorapaxar is contraindicated in patients with a history of stroke, transient ischemic attack (TIA), or intracranial bleeding. The risk of intracranial bleeding is higher in these patients.

Troleandomycin has a major potential interaction with Liver Disease.

Troleandomycin is primarily excreted by the liver and may accumulate in patients with impaired hepatic function. In addition, the use of troleandomycin has been associated with an allergic type of cholestatic hepatitis, particularly in patients receiving the drug for more than 2 weeks or given repeated courses. Therapy with troleandomycin should be administered cautiously in patients with liver and/or biliary disease. Liver function tests should be monitored during prolonged or repeated courses of therapy, and the drug discontinued if abnormalities develop.

Vorapaxar has a major potential interaction with Liver Disease.

No dose adjustment is required in patients with renal dysfunction or mild to moderate hepatic impairment. Vorapaxar is not recommended in patients with severe hepatic impairment due to bleeding risk.

Troleandomycin has a major potential interaction with Noninfectious Colitis.

Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis. The most common culprits include clindamycin and lincomycin. Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development. Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea after antibacterial use. Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary. Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity. Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed. Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.

Vorapaxar has a major potential interaction with Peptic Ulcer.

Vorapaxar increases the risk of bleeding and it is contraindicated in patients with active pathological bleeding such as intracranial hemorrhage or peptic ulcer. In other patients, consider the underlying risk of bleeding before initiating therapy. General risk factors include older age, low body weight, reduced renal or hepatic function, history of bleeding disorders, and use of certain concomitant medications. The use of warfarin and other anticoagulants should be avoided. Bleeding should be suspected in any patient who is hypotensive and has recently undergone coronary angiography, percutaneous coronary intervention (PCI), coronary artery bypass graft surgery (CABG), or any other surgical procedure.